-
Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the conference, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented a comprehensive overview of the latest advances, current standards, and future directions in first-line treatment for chronic lymphocytic…
-
Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic…
-
Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. As a malignant plasma cell disorder predominantly affecting older adults, multiple myeloma (MM) requires continuous advancement in standardized diagnosis, scientific innovation, and patient-centered management, all of which are critical to…
-
Annual Review | Professor Xiuli Ju: Advances in the Diagnosis and Treatment of Pediatric Mature B-Cell Lymphoma
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Leading experts and scholars from across China presented advances in both basic and clinical research in leukemia, lymphoma, and myeloma, addressing key challenges in real-world practice and exploring new therapeutic…
-
Lymphoma Insights · ASH Special | Professor Qinqing Cai: New Advances in the Treatment of Relapsed/Refractory Marginal Zone Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) recently concluded successfully in Orlando, USA. As the most influential annual event in hematology, this year’s meeting showcased multiple breakthrough advances in lymphoma, offering new directions for optimizing clinical practice.
-
Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?
The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.
-
Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy
From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and key clinical challenges, with the goal of fostering academic innovation and supporting the growth of emerging clinicians.
-
Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations
The Infectious Diseases Society of America (IDSA) has recently released its Clinical Practice Guidelines for the Treatment and Management of Complicated Urinary Tract Infections (cUTI)—the first IDSA guideline dedicated specifically to cUTI. The updated guideline revises the definition of cUTI and proposes a four-step framework to support individualized empiric treatment decisions.
Connecting Medical Expertise through Media